Tonsillectomy Bleeding
Conditions
Interventions
63 children between 2 and 12 years old with an indication for tonsillectomy were recruited. Those responsible filled out a demographic data and Von Wollebrand type I questionnaire. The children were r
Sponsors
Associação Paranaense de Cultura
Eligibility
Age
2 Years to 12 Years
Inclusion criteria
Inclusion criteria: Be under 12 years old; tonsillectomy indication due to recurrent infections or adenotonsillar hypertrophy.
Exclusion criteria
Exclusion criteria: Suspected von Willebrand type 1 disease; operation in the last two months; with a history of infectious processes in the last month; altered coagulogram; other coagulation disorders; use of drugs that can interfere with blood coagulation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinically significant difference of twenty-five milliliters in the volume of bleeding during tonsillectomy surgery between the tranexamic acid and placebo groups.Verified by measuring the volume of blood lost during surgery in milliliters (mL) assessed through the collector's check.;When evaluating the volume in milliliters of blood lost in the procedure, no significant result was found between the use of ATX or not (p = 0.66). | — |
Secondary
| Measure | Time frame |
|---|---|
| Variation in time of surgery in minutes between tranexamic acid and placebo groups.It was evaluated by timing the surgeries.;The use of ATX did not significantly influence the duration of the surgery (p = 0.88).;Assessment of adverse effects with the use of tranexamic acid. Assessments of adverse effects were made during the operation, 8 hours after the procedure and / or at discharge. Participants and guardians were asked about possible common adverse effects of ATX such as: skin reaction, nausea, emesis, headache, diarrhea, seizure, dizziness or vertigo. The severity of possible adverse effects was assessed using the CTCAE scale.;No adverse effects were found in any of the participating patients, either in the group using tranexamic acid or in the placebo. | — |
Countries
Brazil
Contacts
Public ContactMarco Fornazieri
Clinica Olfact
Outcome results
None listed